PremiumThe FlyKodiak Sciences completes enrollment in GLOW2 Phase 3 trial Kodiak Sciences granted orphan designation for tabirafusp alfa Biotech Alert: Searches spiking for these stocks today PremiumThe FlyKodiak Sciences price target raised to $4 from $3 at Barclays Kodiak Sciences Reports Q3 2024 Financial Results Kodiak Sciences reports Q3 EPS (84c), consensus (90c) PremiumPre-EarningsKOD Earnings this Week: How Will it Perform? Kodiak Sciences reports Q1 EPS (82c), consensus ($1.07) Kodiak Sciences announces treatment of first patients in Phase3 Tarcocimab study 
